## **Izertis**

# Sponsored Research Spain | Technology


Investment Research



#### **Company Flash Note**

Buy Recommendation unchanged Share price: EUR 8.20 closing price as of 06/04/2022 9.70 Target price: EUR from Target Price: EUR 9 70 **Upside/Downside Potential** 18.3% Reuters/Bloomberg IZER.MC/IZER SM Market capitalisation (EURm) 192 Current N° of shares (m) 23 23% Free float Daily avg. no. trad. sh. 12 mth (k) 12 Daily avg. trad. vol. 12 mth (k) 71.95 Price high/low 12 months 9.64 / 7.18 Abs Perfs 1/3/12 mths (%) 9.92/2.50/-12.39 12/22e 12/23e Key financials (EUR) 12/21 Sales (m) 65 95 126 FBITDA (m) 10 14 EBITDA margin 11.2% 10.9% 11.0% EBIT (m) 2 3 EBIT margin 2.6% 3.6% 4.4% Net Profit (adj.)(m) 0 1 3 3.2% 5.2% 6.9% Net debt/(cash) (m) 14 22 31 Net Debt Equity 0.4 0.7 0.9 Net Debt/EBITDA 2.0 2.2 2.2 Int. cover(EBITDA/Fin.int) 8.5 8.6 9.5 EV/Sales 3.0 2.2 1.7 FV/FBITDA 26.9 20.2 15.7 EV/EBITDA (adj.) 26.9 20.2 15.7 EV/EBIT 61.1 39.4 P/E (adj.) nm nm nm P/BV 5.8 6.1 5.6 OpFCF yield 0.4% 3.0% 4.4% Dividend yield 0.0% 0.0% 0.0% EPS (adj.) 0.02 0.06 0.12 **BVPS** 1.37 1.35 1.47 DPS 0.00 0.00 0.00

Laren Capital, S.L.U. 59%; Management Team 15%; Santander AM 2%;



#### Analyst(s)

**Shareholders** 

Juan Peña juan.pena@gvcgaesco.es +34 91 436 78 16

#### Reason: Company results (post view)

7 April 2022

#### Mejora de márgenes y aceleración del crecimiento

La compañía presentó ayer resultados del ejercicio FY21 en los que se muestra un crecimiento ligeramente superior a nuestras estimaciones (EUR65M de ingresos vs EUR63.5m estimados y EUR7.3m de EBITDA recurrente vs EUR6.9m estimados), siendo lo más relevante la mejora de márgenes (11.2% vs 10.9% estimado). Asimismo, se observa una aceleración del crecimiento orgánico de la compañía en la segunda mitad del año, reflejando la fortaleza de sus negocios principales. La situación financiera presenta una deuda neta de EUR14.3m (1.98x DN/EBITDA) en línea con nuestras estimaciones.

- ✓ Las dos **líneas de ingresos de mayor valor añadido** y crecimiento (Digital Transformation y Technological Infrastructure & Services) continúan ganando peso sobre el total y ya suponen un 70% de los ingresos (vs 59% en FY20). El **crecimiento orgánico de dichas líneas es del +14.3% y +25.2%** en el año respectivamente, por encima de nuestras estimaciones en torno al +10%.
- ✓ Por otro lado, las líneas de negocio con menor valor añadido (Business Operations y Business Solutions) han tenido un mejor desempeño del esperado con una estabilización de ingresos en BOs y una caída del -13.4% en BSs.
- ✓ Esta aceleración del crecimiento de las líneas de negocio con mayor valor añadido permite que el margen de EBITDA normalizado (excluyendo gastos extraordinarios, que en FY21 únicamente son de EUR94k) ascienda al 11.2%, mejorando nuestras estimaciones y por encima del 10% marcado como objetivo por la compañía en su Plan Estratégico 2023.
- ✓ En relación al crecimiento inorgánico, otra de las bases del crecimiento de la compañía, se han realizado una pequeña adquisición con EUR2m de facturación y se prevé que se cierren más durante las próximas semanas. Nuestras estimaciones reflejan una aportación incremental de ingresos por M&A de EUR19m en 2022, para cerrar 2022 entre EUR90-95m de facturación y c.EUR10m de EBITDA normalizado.
- ✓ Pese al fuerte esfuerzo inversor realizado durante 2021 (con c.EUR9m de inversión en M&A), la deuda neta se mantiene en torno a 2x, objetivo marcado por la compañía.
- ✓ El beneficio neto de la compañía es menor que en 2020 derivado de unos ingresos extraordinarios por EUR2.3m por operaciones de venta de activos. El beneficio neto comparable crece en 2021 hasta los EUR0.4m.
- ✓ Mantenemos nuestras estimaciones para 2022 con una ligera caída de márgenes en previsión de posibles impactos derivados de los sucesos macroeconómicos que estamos sufriendo y adoptando una posición conservadora. Pensamos que la compañía está muy bien posicionada para capturar el gran valor que existe en la industria y el crecimiento que está llevando demuestra que está creciendo muy por encima del mercado.
- Mantenemos nuestra visión positiva sobre la compañía y reiteramos nuestro precio objetivo en EUR9.7 por acción con recomendación de Comprar.





#### **Resultados FY 21**

#### IZERTIS. POST-FY'21 RESULTS.

| EURm                                     | FY'20  | FY'21  | Δ% y/y  |
|--|--------|--------|---------|
| Total income                             | 52.86  | 67.99  | 28.6%   |
| Digital Transformation                   | 15.61  | 26.94  | 72.6%   |
| Technological Infrastructures & Services | 14.16  | 18.33  | 29.4%   |
| Business Operations                      | 10.54  | 10.81  | 2.5%    |
| Business Solutions                       | 10.19  | 8.82   | -13.4%  |
| Others                                   | 0.24   | 0.15   | -36.6%  |
| Other income (non operative)             | 2.12   | 2.95   | 39.2%   |
| Supplies                                 | -15.90 | -17.62 | 10.8%   |
| Gross margin                             | 36.96  | 50.38  | 36.3%   |
| % gross margin                           | 69.9%  | 74.1%  | 4.2pp   |
| Personnel costs                          | -28.54 | -39.56 | 38.6%   |
| Other general costs                      | -3.86  | -4.17  | 8.2%    |
| Other results                            | 3.09   | 0.53   | -83.0%  |
| Impairment & Results of sale of assets   | -2.39  | 0.10   | n.a     |
| EBITDA                                   | 7.66   | 7.18   | -6.1%   |
| other non recurrent costs                | -2.39  | 0.09   | -103.9% |
| Normalized EBITDA                        | 5.27   | 7.27   | 38.0%   |
| Normalized EBITDA mg (%)                 | 10.4%  | 11.2%  | .8рр    |
| EBIT                                     | 3.78   | 1.58   | -58.2%  |
| Net income                               | 1.38   | 0.39   | -71.6%  |

Source: Izertis & GVC Gaesco Valores

La mejora del margen bruto refleja la capacidad de la compañía para traspasar incrementos de costes a sus clientes en un contexto inflacionario. No obstante, hay que tener en cuenta que la inflación en 2021 aún se situaba a niveles "razonables". A nivel costes indirectos, también se observa una mejora del margen EBITDA normalizado por lo que los incrementos de costes de personal y generales también se están logrando soportar con los crecimientos de ingresos.

IZERTIS. POST-FY'21 RESULTS. Organic & Inorganic

| EURm                                     | FY'20 | FY'21 | Δ% y/y | Δ% y/y<br>org. |  |
|--|-------|-------|--------|----------------|--|
| Net income                               | 50.50 | 64.89 | 28.5%  | 8.9%           |  |
| Digital Transformation                   | 15.61 | 26.94 | 72.6%  | 14.3%          |  |
| Technological Infrastructures & Services | 14.16 | 18.33 | 29.4%  | 25.2%          |  |
| Business Operations                      | 10.54 | 10.81 | 2.5%   | 0.6%           |  |
| Business Solutions                       | 10.19 | 8.82  | -13.4% | -13.4%         |  |

Estos crecimientos orgánicos son superiores a los observados durante H121 que eran del +10.3% y del +24.7% respectivamente, lo que sugiere una aceleración del crecimiento durante la segunda mitad del año.





| zertis: Summary tables PROFIT & LOSS (EURm)                           | 12/2019                        | 12/2020                        | 12/2021               | 12/2022e               | 12/2023e                       | 12/2024          |
|---|--------------------------------|--------------------------------|-----------------------|------------------------|--------------------------------|------------------|
| Sales   | 46.3                           | 50.7                           | 65.0                  | 94.7                   | 126                            | 15               |
| Cost of Sales & Operating Costs                                       | -41.7                          | -45.5                          | -57.8                 | -84.4                  | -112.3                         | -134.            |
| Non Recurrent Expenses/Income   | 0.0                            | 0.0                            | 0.0                   | 0.0                    | 0.0                            | 0.               |
| EBITDA  | 4.6<br>4.6                     | 5.3<br>5.3                     | 7.3<br>7.3            | 10.4<br>10.4           | 13.9<br>13.9                   | 16.<br>16.       |
| EBITDA (adj.)*<br>Depreciation  | -3.0                           | -3.9                           | -5.6                  | -6.9                   | -8.4                           | -9.              |
| EBITA   | -3.0<br><b>1.6</b>             | -5.9<br><b>1.4</b>             | 1. <b>7</b>           | 3.4                    | 5.5                            | -s.<br>7.        |
| EBITA (adj)*  | 1.6                            | 1.4                            | 1.7                   | 3.4                    | 5.5                            | 7.               |
| Amortisations and Write Downs   | 0.0                            | 0.0                            | 0.0                   | 0.0                    | 0.0                            | 0.               |
| BIT   | 1.6                            | 1.4                            | 1.7                   | 3.4                    | 5.5                            | 7                |
| EBIT (adj.)*  | 1.6                            | 1.4                            | 1.7                   | 3.4                    | 5.5                            | 7                |
| Net Financial Interest  | -0.4                           | -1.4                           | -0.9                  | -1.2                   | -1.5                           | -1               |
| Other Financials  | 0.0                            | 0.0                            | 0.0                   | 0.0                    | 0.0                            | 0                |
| Associates  | -0.1<br>-0.6                   | -0.4<br>2.4                    | 0.0                   | 0.0<br>-0.3            | 0.0<br>-0.3                    | 0<br>-0          |
| Other Non Recurrent Items  Earnings Before Tax (EBT)                  | -0.6<br><b>0.5</b>             | 1.9                            | -0.1<br><b>0.7</b>    | -0.3<br><b>1.9</b>     | -0.3<br><b>3.7</b>             | -0<br><b>5</b>   |
| Tax   | -0.2                           | -0.5                           | -0.3                  | -0.5                   | -0.9                           | -1               |
| Tax rate  | 46.3%                          | 27.9%                          | 45.8%                 | 25.0%                  | 25.0%                          | 25.0°            |
| Discontinued Operations   | 0.0                            | 0.0                            | 0.0                   | 0.0                    | 0.0                            | 0                |
| Minorities  | 0.0                            | 0.0                            | 0.0                   | 0.0                    | 0.0                            | 0                |
| Net Profit (reported)   | 0.3                            | 1.4                            | 0.4                   | 1.4                    | 2.8                            | 4                |
| Net Profit (adj.)   | 0.3                            | 1.4                            | 0.4                   | 1.4                    | 2.8                            | 4                |
| CASH FLOW (EURm)  | 12/2019                        | 12/2020                        | 12/2021               | 12/2022e               | 12/2023e                       | 12/2024          |
| Cash Flow from Operations before change in NWC                        | 3.4                            | 5.7                            | 6.0                   | 8.4                    | 11.2                           | 13               |
| Change in Net Working Capital   | 0.2                            | 0.5                            | -3.4                  | -0.5                   | -0.4                           | -0               |
| cash Flow from Operations Capex                                       | <b>3.5</b><br>-2.5             | <b>6.2</b><br>-1.6             | <b>2.6</b><br>-1.9    | <b>7.8</b><br>-2.0     | <b>10.8</b><br>-2.3            | <b>13</b><br>-2  |
| let Financial Investments   | 0.0                            | 0.0                            | -1.9<br>-1.8          | -2.0<br>-14.1          | -2.3<br>-17.8                  | -2<br>-13        |
| ree Cash Flow   | 1.1                            | 4.5                            | -1.1                  | -8.3                   | <b>-9.3</b>                    | -1               |
| Dividends   | 0.0                            | 0.0                            | 0.0                   | 0.0                    | 0.0                            | 0                |
| Other (incl. Capital Increase & share buy backs)                      | -2.4                           | 0.1                            | -3.6                  | 0.3                    | 0.5                            | 0                |
| Change in Net Financial Debt  | -1.4                           | 4.7                            | -4.7                  | -8.0                   | -8.7                           | -1               |
| NOPLAT  | 1.6                            | 1.4                            | 1.7                   | 3.4                    | 5.5                            | 7.               |
| BALANCE SHEET & OTHER ITEMS (EURm)                                    | 12/2019                        | 12/2020                        | 12/2021               | 12/2022e               | 12/2023e                       | 12/2024          |
| let Tangible Assets   | 1.9                            | 1.8                            | 1.6                   | 1.7                    | 1.7                            | 1                |
| Net Intangible Assets (incl.Goodwill)                                 | 20.2                           | 26.7                           | 39.6                  | 52.8                   | 66.6                           | 72               |
| Right-of-Use Assets (Lease Assets)                                    | 0.0                            | 0.0                            | 0.0                   | 0.0                    | 0.0                            | 0                |
| let Financial Assets & Other<br>otal Fixed Assets                     | 3.1<br><b>25.2</b>             | 5.5<br><b>33.9</b>             | 5.6<br><b>46.9</b>    | 5.2<br><b>59.7</b>     | 4.9<br><b>73.3</b>             | 4<br><b>78</b>   |
| nventories  | 0.0                            | 0.4                            | 0.8                   | 0.9                    | 0.9                            | 1                |
| rade receivables  | 12.9                           | 12.3                           | 14.6                  | 15.8                   | 16.9                           | 17               |
| Other current assets  | 2.1                            | 0.7                            | 1.1                   | 1.2                    | 1.3                            | 1                |
| Cash (-)  | -4.2                           | -15.0                          | -37.7                 | -37.4                  | -38.1                          | -38              |
| otal Current Assets   | 19.2                           | 28.5                           | 54.3                  | 55.2                   | 57.2                           | 59               |
| otal Assets   | 44.4                           | 62.4                           | 101.2                 | 114.9                  | 130.5                          | 137              |
| Shareholders Equity   | 15.6                           | 23.6                           | 32.0                  | 31.6                   | 34.3                           | 38               |
| linority<br>otal Equity   | 0.2<br><b>15.7</b>             | 0.2<br><b>23.8</b>             | 0.3<br><b>32.2</b>    | 0.3<br><b>31.8</b>     | 0.3<br><b>34.6</b>             | 0<br><b>38</b>   |
| ong term interest bearing debt  | 9.1                            | <b>23.6</b><br>16.8            | 35.3                  | 42.4                   | 51.4                           | 53               |
| rovisions   | 0.0                            | 0.0                            | 0.0                   | 0.0                    | 0.0                            | 0                |
| ease Liabilities  | 0.0                            | 0.0                            | 0.0                   | 0.0                    | 0.0                            | Ö                |
| Other long term liabilities   | 1.7                            | 3.8                            | 5.0                   | 4.8                    | 4.5                            | 4                |
| otal Long Term Liabilities  | 10.8                           | 20.6                           | 40.3                  | 47.2                   | 55.9                           | 57               |
| hort term interest bearing debt                                       | 9.4                            | 7.9                            | 16.8                  | 17.3                   | 17.8                           | 17               |
| rade payables   | 5.4                            | 5.7                            | 5.1                   | 5.7                    | 6.5                            | 7                |
| other current liabilities   | 3.1                            | 4.3                            | 6.8                   | 12.9                   | 15.7                           | 16               |
| otal Current Liabilities  | 17.9<br>44.4                   | 17.9<br>62.4                   | 28.6                  | 35.9                   | 40.0<br>120.5                  | 41               |
| otal Liabilities and Shareholders' Equity<br>let Capital Employed     | 44.4<br>31.8                   | 62.4<br>37.4                   | 101.2<br>51.6         | 114.9<br>59.0          | 130.5<br>70.2                  | 137<br>75        |
| let Working Capital   | 7.5                            | 7.0                            | 10.4                  | 11.0                   | 70.2<br>11.4                   | 11               |
| ROWTH & MARGINS   | 12/2019                        | 12/2020                        | 12/2021               | 12/2022e               | 12/2023e                       | 12/202           |
| NOW III & WANGING   |                                |                                |                       |                        |                                | 19.8             |
| Cales growth  | 26 1%                          | 9.5%                           | /0 / 7/0              | 4:) 1) 70              | .3.3 .3 7/0                    |                  |
|   | 26.1%<br><b>40.8%</b>          | 9.5%<br><b>14.2%</b>           | 28.2%<br><b>38.0%</b> | 45.6%<br><b>42.3%</b>  | 33.3%<br><b>34.6%</b>          |                  |
| Sales growth<br>E <b>BITDA (adj.)* growth</b><br>EBITA (adj.)* growth | 26.1%<br><b>40.8%</b><br>26.7% | 9.5%<br><b>14.2%</b><br>-13.2% | 38.0%<br>20.3%        | <b>42.3%</b><br>104.3% | 33.3%<br><b>34.6%</b><br>61.8% | <b>21.2</b> 37.7 |





| Izertis: Summary tables                     | 40/0040            | 40/0000           | 40/0004            | 40/0000-           | 40/0000-           | 40/0004            |
|---|--------------------|-------------------|--------------------|--------------------|--------------------|--------------------|
| GROWTH & MARGINS                            | 12/2019            | 12/2020           | 12/2021            | 12/2022e           | 12/2023e           | 12/2024e           |
| Net Profit growth                           | -55.3%             | 447.6%            | -71.6%             | 263.9%             | 97.0%              | 52.9%              |
| EPS adj. growth                             | -55.3%             | 440.4%            | -73.8%             | 263.9%             | 97.0%              | 52.9%              |
| DPS adj. growth                             | 40.00/             | 40.40/            | 44.007             | 40.00/             | 44.00/             | 44.00/             |
| EBITDA (adj)* margin                        | 10.0%              | 10.4%             | 11.2%              | 10.9%              | 11.0%              | 11.2%              |
| EBITA (adj)* margin                         | 3.5%               | 2.7%              | 2.6%               | 3.6%               | 4.4%               | 5.0%               |
| EBIT (adj)* margin                          | 3.5%               | 2.7%              | 2.6%               | 3.6%               | 4.4%               | 5.0%               |
| RATIOS                                      | 12/2019            | 12/2020           | 12/2021            | 12/2022e           | 12/2023e           | 12/2024e           |
| Net Debt/Equity                             | 0.9                | 0.4               | 0.4                | 0.7                | 0.9                | 0.8                |
| Net Debt/EBITDA                             | 3.1                | 1.8               | 2.0                | 2.2                | 2.2                | 1.9                |
| Interest cover (EBITDA/Fin.interest)        | 11.8               | 3.7               | 8.5                | 8.6                | 9.5                | 10.7               |
| Capex/D&A                                   | 81.6%              | 42.3%             | 34.5%              | 29.3%              | 27.3%              | 23.7%              |
| Capex/Sales                                 | 5.3%               | 3.2%              | 3.0%               | 2.1%               | 1.8%               | 1.5%               |
| NWC/Sales                                   | 16.3%              | 13.9%             | 16.0%              | 11.6%              | 9.0%               | 7.6%               |
| ROE (average)                               | 2.1%               | 7.0%              | 1.4%               | 4.5%               | 8.5%               | 11.8%              |
| ROCE (adj.)                                 | 5.4%               | 3.9%              | 3.2%               | 5.2%               | 6.9%               | 8.9%               |
| WACC  | 8.5%               | 8.5%              | 8.5%               | 8.5%               | 8.5%               | 8.5%               |
| ROCE (adj.)/WACC                            | 0.6                | 0.5               | 0.4                | 0.6                | 0.8                | 1.1                |
| PER SHARE DATA (EUR)***                     | 12/2019            | 12/2020           | 12/2021            | 12/2022e           | 12/2023e           | 12/2024e           |
| Average diluted number of shares            | 21.3               | 21.6              | 23.4               | 23.4               | 23.4               | 23.4               |
| EPS (reported)                              | 0.01               | 0.06              | 0.02               | 0.06               | 0.12               | 0.18               |
| EPS (adj.)                                  | 0.01               | 0.06              | 0.02               | 0.06               | 0.12               | 0.18               |
| BVPS  | 0.73               | 1.09              | 1.37               | 1.35               | 1.47               | 1.65               |
| DPS   | 0.00               | 0.00              | 0.00               | 0.00               | 0.00               | 0.00               |
| VALUATION                                   | 12/2019            | 12/2020           | 12/2021            | 12/2022e           | 12/2023e           | 12/2024e           |
| EV/Sales                                    | 2.0                | 3.3               | 3.0                | 2.2                | 1.7                | 1.5                |
| EV/EBITDA                                   | 20.5               | 31.7              | 26.9               | 20.2               | 15.7               | 13.0               |
| EV/EBITDA (adj.)*                           | 20.5               | 31.7              | 26.9               | 20.2               | 15.7               | 13.0               |
| EV/EBITA                                    | 59.1               | 120.0             | 116.9              | 61.1               | 39.4               | 28.8               |
| EV/EBITA (adj.)*                            | 59.1               | 120.0             | 116.9              | 61.1               | 39.4               | 28.8               |
| EV/EBIT                                     | 59.1               | n.m.              | n.m.               | 61.1               | 39.4               | 28.8               |
| EV/EBIT (adj.)*                             | 59.1               | n.m.              | n.m.               | 61.1               | 39.4               | 28.8               |
| P/E (adj.)                                  | n.m.               | n.m.              | n.m.               | n.m.               | n.m.               | 44.8               |
| P/BV  | 5.4                | 6.9               | 5.8                | 6.1                | 5.6                | 5.0                |
| Total Yield Ratio                           | 0.0%               | 0.0%              | 0.0%               | 0.0%               | 0.0%               | 0.0%               |
| EV/CE                                       | 3.2                | 4.7               | 3.8                | 3.2                | 2.7                | 2.6                |
| OpFCF yield                                 | 1.3%               | 2.8%              | 0.4%               | 3.0%               | 4.4%               | 5.8%               |
| OpFCF/EV                                    | 1.1%               | 2.7%              | 0.3%               | 2.8%               | 3.9%               | 5.1%               |
| Payout ratio                                | 0.0%               | 0.0%              | 0.0%               | 0.0%               | 0.0%               | 0.0%               |
| Dividend yield (gross)                      | 0.0%               | 0.0%              | 0.0%               | 0.0%               | 0.0%               | 0.0%               |
| EV AND MKT CAP (EURm)                       | 12/2019            | 12/2020           | 12/2021            | 12/2022e           | 12/2023e           | 12/2024e           |
| Price** (EUR)                               | 3.92               | 7.54              | 7.98               | 8.20               | 8.20               | 8.20               |
| Outstanding number of shares for main stock | 21.3               | 21.6              | 23.4               | 23.4               | 23.4               | 23.4               |
| Total Market Cap                            | 83.5               | 162.8             | 186.8              | 192.0              | 192.0              | 192.0              |
| Gross Financial Debt (+)                    | 18.5               | 24.7              | 52.1               | 59.7               | 69.2               | 71.1               |
| Cash & Marketable Securities (-)            | -4.2               | -15.0             | -37.7              | -37.4              | -38.1              | -38.9              |
| Not Financial Date                          | 14.4               | 9.7               | 14.4               | 22.4               | 31.1               | 32.3               |
| Net Financial Debt                          |                    |                   |                    |                    |                    |                    |
| Lease Liabilities (+)                       | 0.0                | 0.0               | 0.0                | 0.0                | 0.0                | 0.0                |
|   | 0.0<br><b>14.4</b> | 0.0<br><b>9.7</b> | 0.0<br><b>14.4</b> | 0.0<br><b>22.4</b> | 0.0<br><b>31.1</b> | 0.0<br><b>32.3</b> |
| Lease Liabilities (+)                       |                    |                   |                    |                    |                    |                    |

Source: Company, GVC Gaesco Valores estimates.

#### Notes

#### Sector: Technology/Computer Services

Company Description: Izertis is a technological consulting company that helps customers through its digital transformation with a broad portolio of services. The company has founded in 1996 by its Presidente and CEO and its growth has been constant since then. Now the company is in a growth momentum both organically and inorganically to consolidate the market.



<sup>\*</sup> Where EBITDA (adj.) or EBITA (adj)= EBITDA (or EBITA) -/+ Non Recurrent Expenses/Income and where EBIT (adj)= EBIT-/+ Non Recurrent Expenses/Income - PPA amortisation

<sup>\*\*</sup>Price (in local currency): Fiscal year end price for Historical Years and Current Price for current and forecasted years

<sup>\*\*\*</sup>EPS (adj.) diluted= Net Profit (adj.)/Avg DIL. Ord. (+ Ord. equivalent) Shs. EPS (reported) = Net Profit reported/Avg DIL. Ord. (+ Ord. equivalent) Shs.



Information regarding Market Abuse and Conflicts of Interests and recommendation history available in our web page: www.gvcgaesco.es. GVC Gaesco Valores S.V., S.A., is a company regulated by the CNMV and is registered under number 182 in the Official Register of Securities Companies and Agencies of the CNMV.

All the information contained in this report has been compiled and prepared in good faith by GVC Gaesco Valores S.V., S.A. from sources we believe to be reliable (including public accounts and audits). The opinions expressed in this report are those of our research department at the time of publication and may be changed at any time without notice and without communication. There is no scheduled frequency for updating the recommendations. The recommendation contained in this document has not been communicated in advance to the issuer. This document does not constitute an invitation to buy or sell securities. GVC Gaesco Valores S.V., S.A. accepts no responsibility for the use of this report. GVC Gaesco Valores S.V., S.A. has no proprietary investment positions in the securities mentioned in this report. There may be a business relationship between GVC Gaesco Valores S.V., S.A., and the issuer on which this report is issued, and if so, this is detailed in the following section. This and other documents are only one source of information, among others, which is not intended in itself to constitute an investment decision tool. In no way can this or any other analysis documents produced by us be used for investment decisions. Each investor is responsible for his or her own decisions and this document or others are only a source of supplementary information. This document has been distributed only to professional, qualified and selected investors or potential investors and has not been distributed in a generic form. Any use of this document implies an understanding and explicit acceptance of these warnings.

#### As of the date of this report, GVC Gaesco Valores S.V., S.A.,

- acts as registered advisor, agent or liquidity provider for the following companies: Catenon SA; Clever Global SA; Facephi Biometría SA., Griñó Ecologic SA, NBI Bearings Europe S.A.; Trajano Iberia (Socimi), SA; Asgard Investment Hotels (antes Obsido Socimi SA); Eurona Telecom SA; IFFE Futura, S.A.; Secuoya Grupo de Comunicación SA; Mercal Inmuebles (Socimi); Student Properties Spain (Socimi); Solaria Casiopea (bonos MARF); Atrys Health; Quonia (Socimi); TIER1 Technology; Excem Capital Partners Sociedad de Inversión Residencial (Socimi YEXR); Agile Content; Imaginarium, SA. ENCE Energia y Celulosa; Plásticos Compuestos SA; Holaluz Clidom SA; ASPY Global Services, S.A. Pangaea Oncology, S.A.; Investment Media Optimisation SA, Inmobiliaria del Sur S.A., Club de Futbol Intercity, S.A.D (CITY); Profithol S.A. (SPH); Vytrus Biotech.
- has participated and/or participates as lead or co-lead manager in corporate operations with the following companies: Lleidanetworks Serveis Telematics SA; ADL Bionatur Solutions; Plásticos Compuestos SA; Holaluz Clidom SA; ASPY Global Services, S.A; The Nimo's Holding; Parlem Telecom Companyia de Telecomunicaciones SA; Almagro Capital Socimi SA; Profithol S.A. (SPH)
- has a liquidity contract as outlined by the CNMV's Circular 1/2017 with: Melia Hotels International; Española de Viviendas en Alquiler S.A. (CEVASA); eDreams ODIGEO; ENCE Energia y Celulosa; Cementos Molins, Deoleo; Atrys Health;
- has signed a Corporate Brokerage agreement that includes a contractually agreed provision of research services that in return, GVC Gaesco Valores receives a compensation. These reports (sponsored) may/could have been been previously shown to the companies: Agile Content; Atrys Health; Audax Renovables; Gigas Hosting; Catenon; Greenalia; Quabit Inmobiliaria; TIER1 Technology; ADL Bionatur Solutions; Codere SA; Vytrus Biotech. Dichos servicios incluyen informes que han podido ser vistos previamente por las empresas citadas.

#### **Recommendation history for IZERTIS**

| Date      | Recommendation | Target price | Price at change date |
|-----------|----------------|--------------|----------------------|
| 29-Nov-21 | Buy            | 9.70         | 7.20                 |

Source: Factset & ESN, price data adjusted for stock splits.

This chart shows GVC Gaesco Valores continuing coverage of this stock; the current analyst may or may not have covered it over the entire period. Current analyst: Juan Peña (since 24/11/2021)







### **ESN Recommendation System**

The ESN Recommendation System is **Absolute**. It means that each stock is rated based on **total return**, measured by the upside/downside potential (including dividends and capital reimbursement) over a **12-month time horizon**. The final responsible of the recommendation of a listed company is the analyst who covers that company. The recommendation and the target price set by an analyst on one stock are correlated but not totally, because an analyst may include in its recommendation also qualitative elements as market volatility, earning momentum, short term news flow, possible M&A scenarios and other subjective elements.

| SELL | REDUCE | NEUTRAL |    | ACCUMULATE | BUY |
|------|--------|---------|----|------------|-----|
|      | -15%   | -5%     | 5% | 15%        |     |

The ESN spectrum of recommendations (or ratings) for each stock comprises 5 categories: Buy (B), Accumulate (A), Neutral (N), Reduce (R) and Sell (S).


Furthermore, in specific cases and for a limited period of time, the analysts are allowed to rate the stocks as **Rating Suspended (RS)** or **Not Rated (NR)**, as explained below.

#### Meaning of each recommendation or rating:

- Buy: the stock is expected to generate total return of over 15% during the next 12-month
- Accumulate: the stock is expected to generate total return of 5% to 15% during the next 12-month
- Neutral: the stock is expected to generate total return of -5% to +5% during the next 12-month
- Reduce: the stock is expected to generate total return of -5% to -15% during the next 12-month
- Sell: the stock is expected to generate total return under -15% during the next 12-month
- Rating Suspended: the rating is suspended due to: a) a capital operation (take-over bid, SPO, etc.) where a
  Member of ESN is or could be involved with the issuer or a related party of the issuer; b) a change of analyst
  covering the stock; c) the rating of a stock is under review by the Analyst.
- Not Rated: there is no rating for a stock when there is a termination of coverage of the stocks or a company being floated (IPO) by a Member of ESN or a related party of the Member.

Note: a certain flexibility on the limits of total return bands is permitted especially during higher phases of volatility on the markets

#### GVC Gaesco Valores, S.V., S.A.Ratings Breakdown



For full ESN Recommendation and Target price history (in the last 12 months) please see ESN Website <u>Link</u> Date and time of production: 7<sup>th</sup> of April 2022 10:55CET
First date and time of dissemination: 7<sup>th</sup> of April 2022 11:00 CET



#### Disclaimer:

These reports have been prepared and issued by the Members of European Securities Network LLP ('ESN'). ESN, its Members and their affiliates (and any director, officer or employee thereof), are neither liable for the proper and complete transmission of these reports nor for any delay in their receipt. Any unauthorised use, disclosure, copying, distribution, or taking of any action in reliance on these reports is strictly prohibited. The views and expressions in the reports are expressions of opinion and are given in good faith, but are subject to change without notice. These reports may not be reproduced in whole or in part or passed to third parties without permission. The information herein was obtained from various sources. ESN, its Members and their affiliates (and any director, officer or employee thereof) do not guarantee their accuracy or completeness, and neither ESN, nor its Members, nor its Members' affiliates (nor any director, officer or employee thereof) shall be liable in respect of any errors or omissions or for any losses or consequential losses arising from such errors or omissions. Neither the information contained in these reports nor any opinion or omissions. Neither the information contained in these reports nor any opinion expressed constitutes an offer, or an invitation to make an offer, to buy or sell any securities or any options, futures or other derivatives related to such securities ('related investments'). These reports are prepared for the professional clients of the Members of ESN only. They do not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive any of these reports. Investors should seek financial advice reacting the paragraphy of the proposition in any countries to investment. advice regarding the appropriateness of investing in any securities or investment strategies discussed or recommended in these reports and should understand that statements regarding future prospects may not be realised. Investors should note that income from such securities, if any, may fluctuate and that each security's price or value may rise or fall. Accordingly, investors may receive back less than originally invested. Past performance is not necessarily a guide to future performance. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related investment mentioned in these reports. In addition, investors in securities such as ADRs, whose value are influenced by the currency of the underlying security, effectively assume currency risk. ESN, its Members and their affiliates may submit a pre-publication draft without mentioning neither the recommendation nor the target price/fair value) of its reports for review to the Investor Relations Department of the issuer forming the subject of the report, solely for the purpose of correcting any inadvertent material inaccuracies. Like all members employees, analysts receive compensation that is impacted by overall firm profitability For further details about the analyst certification, the specific risks of the company and about the valuation wmethods used to determine the price targets included in this report/note, please refer to the specific disclaimer pages prepared by the ESN Members. In the case of a short note please refer to the latest relevant published research on single stock or contact the analyst named on the front of the report/note for detailed information on the valuation methods, earning estimates and risks. A full description of all the organisational and administrative measures taken by the Members of ESN to manage interest and conflicts of interest are available on the Members of ESN to manage interest and conflicts of interest are available on the website of the Members or in the local disclaimer of the Members or contacting directly the Members. Research is available through the ESN Members sales representative. ESN and/or ESN Members will provide periodic updates on companies or sectors based on company-specific developments or announcements, market conditions or any other publicly available information. Unless agreed in writing with an ESN Member, this research is intended solely for internal use by the recipient. Neither this document nor any copy of it may be taken or transmitted into Australia, Canada or Japan or distributed, directly or indirectly, in Australia, Canada or Japan or to any resident thereof. This document is for distribution in the U.K. only to persons who have professional experience in matters relating to investments and fall within article 19(5) of the financial services and markets act 2000 (financial promotion) order 2005 (the "order") or (ii) are persons falling within article 49(2)(a) to (d) of the order, namely high net worth companies, unincorporated associations etc (all such persons together being referred to as "relevant persons"). This document must not be acted on or relied upon by persons who are not relevant persons. Any investment or investment activity to which this document relates is available only to relevant persons and will be engaged in only with relevant persons. The distribution of this document in other jurisdictions or to residents of other jurisdictions may also be restricted by law, and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. By accepting this report, you agree to be bound by the foregoing instructions. You shall indemnify ESN, its Members and their affiliates (and any director, officer or employee thereof) against any damages, claims, losses, and detriments resulting from or in connection with the unauthorized use of this document. For disclosure upon "conflicts of interest" on the companies under coverage by all the ESN Members, on the "interests" and "conflicts" of the analysts and on each "company recommendation history", please visit the ESN website: o.eu/research and database

or refer to the local disclaimer of the Members, or contact directly the Members:

www.bancaakros.it regulated by the CONSOB - Commissione Nazionale per le Società e la Borsa www.caixabi.pt regulated by the CMVM - Comissão do Mercado de Valores Mobiliários www.cic-marketsolutions.eu regulated by the AMF - Autorité des marchés financiers www.qvcgaesco.es regulated by CNMV - Comisión Nacional del Mercado de Valores

#### Members of ESN (European Securities Network LLP)



Banca Akros SpA Viale Eginardo, 29 20149 Milano Italy

Phone: +39 02 4344 4389



**CIC Market Solutions** 6, avenue de Provence 75441 Paris - Cedex 09 France

Phone: +33 1 5348 8193



Caixa-Banco de Investimento Avenida João XXI, 63 1000-300 Lisboa

Portugal Phone: +351 21 313 7300



GVC Gaesco Valores, S.V., S.A.

C/- Fortuny, 17 28010 Madrid Spain

Phone: +34 91 436 7813

